PR89253

NOTTINGHAM and KEELE, United Kingdom, April 28, 2021 /PRNewswire=KYODO JBN/ --

-- Collaboration investigates enhanced manufacturing of AAV and lentiviral

vectors to improve quality and productivity for gene therapy and vaccine

developers

Albumedix Ltd. ('Albumedix') (https://albumedix.com/ ), an emerging leader in

the enablement of advanced therapies and recognized global leader in

recombinant human albumin (rHA) has today announced an extension to its

research collaboration with Cobra Biologics, the gene therapy division of

Cognate BioServices, a Charles River Laboratories International, Inc. company.

The research collaboration focuses on process optimization and stability

enhancement in scale-up manufacturing of AAV and lentiviral vectors through

Albumedix' proprietary recombinant human albumin-based product.

Logo - https://mma.prnewswire.com/media/1498257/Albumedix_COBRA_Logo.jpg

Additionally, the collaboration aims to advance both up-stream and down-stream

processing of AAV and lentiviral vector manufacturing, including formulation

development for long-term stability.

The advanced therapy space is a fast-moving industry with new innovative and

transformative therapies entering the clinic every day. To increase the chance

of success and broaden patient availability of these therapies, there is a

growing need to ensure robust, scalable and economically viable production.

Since 2019, Cobra Biologics and Albumedix have jointly been engaged in work on

optimizing viral vector manufacturing and production to improve quality and

productivity for gene therapy and vaccine developers. The current collaboration

is an extension of the 2019 research collaboration agreement and contemplates

that both companies further solidify their commitment to a shared goal of

enabling advanced therapy and biopharmaceutical developers to reach patients

worldwide with more scalable therapies.  

Jonas Skjodt Moller, CEO, Albumedix, commented: "We are delighted to have found

a research partner in Cobra, who are as committed as we are in applying

enabling innovation to push the industry forward. With a mission to empower

excellence in advanced therapies, we invest and partner to be at the scientific

forefront, and we look forward to further combine our in-house expertise and

unique stability enhancing benefits of our recombinant human albumin with

Cobra's viral vector production platform."

Dr Daniel Smith, Executive Director of Global Cell & Gene Therapy Portfolio,

Charles River said: "Viral vector manufacturing presents a challenge for gene

therapy and vaccine developers. This collaboration agreement aims to improve

the manufacturing of viral vectors through a combination of our own expertise

alongside that of Albumedix and in particular their recombinant human albumin

products. We are excited to embark on this research project with Albumedix to

optimize viral vector manufacturing to ensure supply can meet the growing

demand of gene therapies."

SOURCE  Albumedix Ltd.